NAD Refers Advertising Claims for ‘Salonpas’ Products to FDA, FTC

New York, NY – Jan. 16, 2013 – The National Advertising Division has referred to the Food and Drug Administration (FDA) and Federal Trade Commission (FTC) advertising claims made by Hisamitsu America, Inc., manufacturer of Salonpas Brand Pain Relief products. The claims at issue were challenged by Pfizer Consumer Healthcare, a competing manufacturer of ThermaCare over-the-counter heat wraps.

NAD is an investigative unit of the advertising industry’s system of self-regulation and it is administered by the Council of Better Business Bureaus.

NAD had requested substantiation for advertising claims that included:

  •  “Salonpas is the strongest labeled pain reliever available without a prescription.”
  •  “It’s proven to relieve mild to tougher, moderate pain. Something no other OTC pain reliever can claim.”
  •  “The only OTC pain reliever labeled to relieve mild to tougher, moderate pain.”
  •  “Salonpas is the only FDA-approved topical pain reliever that provides up to 12 full hours of serious relief.”
  •  “Salonpas is the #1 brand of patches in the world.”
  •  “SALONPAS is the largest brand of pain relief patches in the U.S.”

The company, in response to NAD’s inquiry, declined to participate in the self-regulatory process. The advertiser maintained that the challenged claims were submitted as part of its New Drug Application (NDA) for use on the OTC drug product label which the FDA subsequently approved.

The advertiser argued that its claims truthfully conveyed information that was consistent with its NDA. The advertiser maintained that its products are unique in the OTC external analgesic drug marketplace in the degree of FDA scrutiny and evaluation they have undergone and that it should be free to communicate this information to consumers. Further, the advertiser said that it has made no reference to, or impugned the safety, effectiveness or quality of, competing products, including Pfizer’s ThermaCare products.

NAD, in its decision, noted that the FDA’s approval of the advertiser’s NDA does not preclude NAD review of competitive advertising claims.

Given that the advertiser elected not to participate in a self-regulatory examination, NAD has referred the claims at issue to the FDA and the FTC for further review.

Latest News


Truvani Voluntarily Discontinues Social Media Post and Two Consumer Reviews for Immune Support Following NAD Inquiry into Implied COVID-19 Messages

Following an inquiry by the National Advertising Division (NAD) of BBB National Programs, Nomolotus, LLC d/b/a Truvani discontinued a social media post for its Immune Support dietary supplement (formerly called “Under the Weather”), as well as two customer reviews...
Read more

NAD Refers IV Drips to FDA and FTC for Claims that IV Hydration Therapy Protects Against COVID-19

The National Advertising Division (NAD), a division of BBB National Programs, has referred advertising claims made by IV Drips, Customized IV Hydration & Wellness (“IV Drips”) for its IV Hydration Therapy to the U.S. Food and Drug Administration (FDA) and Federal Trade Commission (FTC) for...
Read more

NAD Finds Certain NanoSeptic Self-Cleaning Surface Claims are Supported; Recommends Modification of Others

Following an inquiry by the National Advertising Division (NAD) initiated as part of its routine monitoring program, NAD determined that NanoTouch Materials, LLC substantiated certain express claims for its NanoSeptic surfaces...
Read more

NAD Recommends Smile Direct Club Discontinue “3x Faster to Use Than Strips” Claim for Tooth Whitening Kit; Finds Certain Other Claims as Puffery

The National Advertising Division (NAD), a division of BBB National Programs, recommended that Smile Direct Club (“SDC”) discontinue its “3x faster to use than strips” claim for its Bright On Whitening Kit. However, NAD concluded that in the absence of...
Read more